SCHEMBL3854088

SCHEMBL3854088

CCN[C@@H](CC)C(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13741705 1.00
Hydrochloric Acid SCHEMBL15413957 0.98 CA1 (0.35)
SCHEMBL17953257 0.83
SCHEMBL20999419 0.83
SCHEMBL12311713 0.83
SCHEMBL24724789 0.83
SCHEMBL12509930 0.82
SCHEMBL18117423 0.82
SCHEMBL16272863 0.82 MMP3 (0.32)
SCHEMBL21206997 0.81 CA1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200231638-A1 STABILIZED ANTI-MICROBIAL PEPTIDES DANA-FARBER CANCER INSTITUTE, INC. 2020-07-23 US disclosed
US-8642584-B2 Method of using PI3K and MEK modulators EXELIXIS, INC. (US) 2014-02-04 US disclosed
US-8399688-B2 Production of levulinic acid, furfural, and gamma valerolactone from C5 and C6 carbohydrates in mono- and biphasic systems using gamma-valerolactone as a solvent WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2013-03-19 US disclosed
US-20120302545-A1 Method of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2012-11-29 US disclosed
US-20120302767-A1 PRODUCTION OF LEVULINIC ACID, FURFURAL, AND GAMMA VALEROLACTONE FROM C5 and C6 CARBOHYDRATES IN MONO- AND BIPHASIC SYSTEMS USING GAMMA- VALEROLACTONE AS A SOLVENT UNITED STATES DEPARTMENT OF ENERGY 2012-11-29 US disclosed
EP-2101759-A1 METHODS OF USING MEK INHIBITORS Exelixis, Inc. (US) 2009-09-23 EP disclosed
WO-2008076415-A1 METHODS OF USING MEK INHIBITORS EXELIXIS, INC. (US) 2008-06-26 WO disclosed